PharmaTher Holdings Ltd. (PHRRF)
| Previous Close | 0.2700 |
| Open | 0.2600 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.2255 - 0.3220 |
| 52 Week Range | 0.1400 - 1.3900 |
| Volume | |
| Avg. Volume | 925,469 |
| Market Cap | 17.413M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Japan Patent Office has issued Japanese Patent No. 6967532 for KETABET™, a combination formulation of FDA-approved ketamine and betaine anhydrous, which has shown in research to enhance the antidepressant effect while having the potential to reduce the known negative side effects of ketamine
- GlobeNewswire
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to treat rare disorders and life-threatening conditions with ketamine TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Or
- GlobeNewswire
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness.Completing microneedle patch research programs with other psychedelics before year-end.Pursuing Phase 2 clinical studies in 2022 with psilocybin and notable psychedelics. TORONTO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company,
